State to receive $35M from settlement with Pfizer
Published: August 11,2014
Tags: Attorney General's Office, court, drug, Jim Hood, justice, lawsuit, medical, medicine, organ transplant, Pfizer Inc. health care, pharmaceutical, Rapamune, settlement, State of Mississippi, Wyeth Pharmaceuticals Inc.
JACKSON — Mississippi will receive $532,675 part of a $35 million settlement with a Pfizer Inc. subsidiary over the marketing of an organ-transplant drug.
Mississippi and 41 other states are involved in the settlement with Pfizer, the parent company of Wyeth Pharmaceuticals Inc. The deal resolves allegations Wyeth misrepresented the uses of the drug Rapamune.
A statement from Mississippi Attorney General Jim Hood says “state consumer protection laws were violated by misrepresentation of the uses and benefits of Rapamune.”
Rapamune was approved to help prevent the rejection of kidney transplants. The states alleged the company promoted it to doctors for uses following other organ transplants.
New York-based Pfizer says in a statement the alleged activity occurred before it acquired Wyeth. Pfizer didn’t admit wrongdoing or liability as part of the settlement.
To sign up for Mississippi Business Daily Updates, click here.
Top Posts & Pages
- Attorney McRae challenging Miss. treasurer in GOP primary
- Judge names receiver for KiOR plant, but tax payment unclear
- DAVID DALLAS — Roger Wicker: Profile in discouragement
- Rival plans filed to end Cleveland schools federal oversight
- Choctaws' new hospital nearing completion
- Ecolab reducing Columbus workforce
- Tommy Robertson indicted on five counts of embezzlement
- Production under way at Grammer AG in Tupelo
- State's ventures into alt-fuel markets net few jobs